Vir Biotechnology, Inc. VIR Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s cumulative cost basis?
- Vir Biotechnology, Inc. (VIR) reported cumulative cost basis of $103.06M in Q1 2026.
- How has Vir Biotechnology, Inc.'s cumulative cost basis changed year-over-year?
- Vir Biotechnology, Inc.'s cumulative cost basis increased by 2.5% year-over-year, from $100.55M to $103.06M.
- What is the long-term trend for Vir Biotechnology, Inc.'s cumulative cost basis?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s cumulative cost basis has grown at a -6.7% compound annual growth rate (CAGR), from $126.35M to $102.78M.